Allogeneic Hematopoietic Stem Cell Transplantation Clinical Trial
Official title:
An Open-Label, Dose-Finding Study of Vedolizumab IV Plus Standard of Care for Graft-Versus-Host Disease (GvHD) Prophylaxis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
The purpose of this study is to assess the initial tolerability, safety and recommended phase 2 dose of vedolizumab intravenous (IV) administered for GvHD prophylaxis along with standard GvHD prophylaxis therapy (in participants undergoing allogeneic hematopoietic stem cell transplantation [allo-HSCT]).
The drug being tested in this study is called Vedolizumab. Vedolizumab (also called MLN0002)
is approved for the treatment of adult participants with moderately to severely active
ulcerative colitis (UC) and Crohn's disease (CD) who achieved an inadequate response, had a
loss of response, or were intolerant to conventional and/or biologic treatments. This study
will look at the tolerability and pharmacokinetics of Vedolizumab in participants undergoing
allo-HSCT when added to standard GvHD prophylaxis (tacrolimus plus short-term methotrexate)
for the prevention of acute GvHD (major complication in allo-HSCT).
The study will enroll approximately 36 participants. Participants will be assigned to
different dose-escalating cohorts in order to find out the recommended phase 2 dose (RP2D) of
the study:
- Cohort 1: Vedolizumab 75 mg
- Cohort 2: Vedolizumab 300 mg
- Cohort 3: Vedolizumab Dose 1
All participants have to receive 1 injection of Vedolizumab on Day -1 before allo-HSCT and on
Days 13 and 42 after allo-HSCT. If none of the participants receiving vedolizumab at 75 mg
experience dose-limiting toxicities (DLTs), dose escalation will continue to 300 mg on Day -1
before allo-HSCT and on Days +13 and +42 after allo-HSCT. If the first 3 participants at 300
mg tolerate the treatment without experiencing DLTs, then the decision on whether to increase
the vedolizumab IV dose in the next cohort will be guided by the PK results.
Cohorts will be escalated in same manner until the identification of RP2D. The cohort at that
dose level may be expanded to include approximately 18 additional participants undergoing
myeloablative conditioning or reduced-intensity conditioning (RIC) and receiving either
related or unrelated allo-HSCT for the treatment of hematologic malignancies or
myeloproliferative neoplasms. This group of participants will allow the further assessment of
the tolerability and clinical activity of vedolizumab.
This multi-center trial will be conducted in the United States. The overall time to
participate in this study will be approximately 2 years. Following the treatment period,
participants who remain in remission will be followed for development of acute and chronic
GvHD and safety during clinic visits at 4, 5, 6, 9, and 12 months after allo-HSCT or until
death or withdrawal of consent or termination of the study by the sponsor. Participants who
complete the study will attend a 12-month follow-up visit. Patients who have been
discontinued from treatment will attend an end of treatment visit 30 to 40 days after the
last dose of study drug using all study procedures outlined for the 12-month follow-up visit.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03294824 -
Non Randomized Comparative Study With Control
|
||
Recruiting |
NCT04098653 -
Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT
|
Phase 2/Phase 3 | |
Recruiting |
NCT03256071 -
Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT
|
Phase 2/Phase 3 | |
Terminated |
NCT02653196 -
A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
|
Early Phase 1 | |
Terminated |
NCT00429039 -
A Study to Accelerate Immune System Recovery Following Stem Cell Transplantation
|
Phase 2 | |
Recruiting |
NCT06028828 -
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Recruiting |
NCT05084027 -
Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT
|
Phase 2 | |
Recruiting |
NCT04123392 -
Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT
|
Phase 2/Phase 3 | |
Recruiting |
NCT05601895 -
The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or Without Sorafenib Maintenance
|
||
Recruiting |
NCT05596968 -
The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT
|
||
Recruiting |
NCT05596981 -
The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT
|
||
Recruiting |
NCT03357172 -
Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Active, not recruiting |
NCT04995653 -
A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT
|
Phase 1 | |
Completed |
NCT02250300 -
MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT04372524 -
Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
|
||
Recruiting |
NCT03593161 -
Humor Therapy and Distress After Allogeneic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT05379569 -
Comparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALL
|
Phase 4 | |
Not yet recruiting |
NCT03902041 -
The Prospective Randomized Controlled Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic HSCT
|
||
Completed |
NCT02270346 -
Inspiratory Muscle Training in Allogeneic Hematopoietic Stem Cell Transplantation Recipients
|
N/A | |
Recruiting |
NCT03297528 -
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
|
Phase 2 |